Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
{"title":"Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.","authors":"","doi":"10.1016/j.cllc.2024.05.005","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div><span>Carboplatin<span>, weekly Paclitaxel (CwP) and </span></span>Pembrolizumab<span> is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%</span></div></span></li><li><span>•</span><span><div>Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population</div></span></li><li><span>•</span><span><div>Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia</div></span></li><li><span>•</span><span><div>Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 7","pages":"Pages e323-e329"},"PeriodicalIF":3.3000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000846","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
Carboplatin, weekly Paclitaxel (CwP) and Pembrolizumab is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%
•
Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population
•
Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia
•
Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%
期刊介绍：
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
